We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$46.6M
Cap. Flow
+$25.8M
Cap. Flow %
13.71%
Top 10 Hldgs %
88.03%
Holding
89
New
10
Increased
1
Reduced
31
Closed
14
Avg Time Held
1.5 quarters
Top 10 Avg Time Held
0.4 quarters
Top 20 Avg Time Held
0.6 quarters

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$38.5M
2
LQDA icon
Liquidia Corp
LQDA
+$268K
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$213K
4
AVBP icon
ArriVent BioPharma
AVBP
+$208K
5
KRYS icon
Krystal Biotech
KRYS
+$207K

Top Sells

Rank Stock Value
1
SERA icon
Sera Prognostics
SERA
+$4.87M
2
DFTX
Definium Therapeutics
DFTX
+$613K
3
TYRA icon
Tyra Biosciences
TYRA
+$613K
4
CYTK icon
Cytokinetics
CYTK
+$547K
5
CMPS
Compass Pathways
CMPS
+$538K

Sector Composition

Rank Sector Weight
1 Miscellaneous 85.52%
2 Healthcare 14.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KYMR icon
26
Kymera Therapeutics
KYMR
$9.35B
$459K 0.24%
4,000
-2,300
-37% -$198K
2025 Q4
2 quarters
DYN icon
27
Dyne Therapeutics
DYN
$3.11B
$444K 0.24%
20,000
– –
2025 Q4
2 quarters
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$31.1B
$441K 0.23%
1,465
– –
2025 Q4
2 quarters
TARS icon
29
Tarsus Pharmaceuticals
TARS
$3.42B
$441K 0.23%
7,000
– –
2025 Q4
2 quarters
SNDX icon
30
Syndax Pharmaceuticals
SNDX
$1.52B
$437K 0.23%
20,000
– –
2025 Q4
2 quarters
EXEL icon
31
Exelixis
EXEL
$14.8B
$435K 0.23%
8,000
-3,948
-33% -$192K
2025 Q4
2 quarters
CRNX
32
DELISTED
Crinetics Pharmaceuticals
CRNX
$412K 0.22%
11,000
– –
2025 Q4
2 quarters
NAMS icon
33
NewAmsterdam Pharma
NAMS
$2.58B
$407K 0.22%
12,000
-3,000
-20% -$98.9K
2025 Q4
2 quarters
ASND icon
34
Ascendis Pharma A/S
ASND
$15.1B
$400K 0.21%
1,500
-1,000
-40% -$234K
2025 Q4
2 quarters
LQDA icon
35
Liquidia Corp
LQDA
$2.45B
$399K 0.21%
+5,000
New +$268K
2026 Q2
0 quarters
STOK icon
36
Stoke Therapeutics
STOK
$1.6B
$393K 0.21%
12,000
– –
2025 Q4
2 quarters
VKTX icon
37
Viking Therapeutics
VKTX
$3.63B
$390K 0.21%
10,000
-5,000
-33% -$162K
2025 Q4
2 quarters
IMNM icon
38
Immunome
IMNM
$2.31B
$381K 0.2%
18,000
-2,000
-10% -$42.8K
2025 Q4
2 quarters
PTGX icon
39
Protagonist Therapeutics
PTGX
$9.3B
$368K 0.2%
3,000
– –
2025 Q4
2 quarters
HRMY icon
40
Harmony Biosciences
HRMY
$2.35B
$364K 0.19%
10,000
-4,283
-30% -$135K
2025 Q4
2 quarters
ELVN icon
41
Enliven Therapeutics
ELVN
$3B
$355K 0.19%
7,000
– –
2026 Q1
1 quarter
SYRE icon
42
Spyre Therapeutics
SYRE
$8.01B
$355K 0.19%
4,000
-1,159
-22% -$84.6K
2025 Q4
2 quarters
NTLA icon
43
Intellia Therapeutics
NTLA
$1.83B
$338K 0.18%
20,000
-6,900
-26% -$96.6K
2026 Q1
1 quarter
MDGL icon
44
Madrigal Pharmaceuticals
MDGL
$10.9B
$322K 0.17%
600
– –
2025 Q4
2 quarters
KNSA icon
45
Kiniksa Pharmaceuticals
KNSA
$6.22B
$320K 0.17%
5,000
-4,000
-44% -$207K
2025 Q4
2 quarters
ALKS icon
46
Alkermes
ALKS
$6.81B
$314K 0.17%
6,000
– –
2025 Q4
2 quarters
TNGX icon
47
Tango Therapeutics
TNGX
$4.01B
$313K 0.17%
10,000
-4,400
-31% -$109K
2026 Q1
1 quarter
ARDX icon
48
Ardelyx
ARDX
$847M
$306K 0.16%
60,000
-20,000
-25% -$122K
2026 Q1
1 quarter
VERA icon
49
Vera Therapeutics
VERA
$2.15B
$300K 0.16%
7,000
-3,000
-30% -$112K
2025 Q4
2 quarters
MIRM icon
50
Mirum Pharmaceuticals
MIRM
$5.58B
$293K 0.16%
2,500
-2,500
-50% -$251K
2025 Q4
2 quarters
1
2
3 4

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
NCPF
Nordflint Capital Partners Fondsmaeglerselskab Copenhagen O, Denmark $188M AUM 64.25% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q2 2026 Portfolio in Review

As of Q2 2026, PSP Research held 89 positions worth $188M, up 33% from $141M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

PSP Research deployed $25.8M of net new capital in Q2 2026, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Liquidia Corp: 5,000 shares worth $399K.

By sector, the portfolio is most concentrated in Miscellaneous at 86% of assets, up from 76% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Definium Therapeutics, an estimated $613K trimmed.

  • PSP Research's largest Q2 2026 buy was Liquidia Corp: 5,000 shares worth $399K.
  • PSP Research added most to State Street SPDR S&P Biotech ETF in Q2 2026, an estimated $38.5M increase.
  • PSP Research's biggest Q2 2026 reduction was Definium Therapeutics, cutting an estimated $613K.
  • PSP Research fully exited Sera Prognostics in Q2 2026, selling an estimated $4.87M.
  • PSP Research's ten largest holdings make up 88% of its $188M portfolio in Q2 2026.
  • PSP Research opened 10 new positions and closed 14 in Q2 2026.
  • PSP Research's portfolio value rose 33% quarter-over-quarter to $188M.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.